We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Stem Cell Breakthrough May Provide New Options for Treatment of Motor Neuron Disease

By LabMedica International staff writers
Posted on 03 Apr 2012
An international group of researchers has created motor neurons using skin cells from a patient with an inherited form of motor neuron disease (MND). More...
The scientists demonstrated that abnormalities of a protein called TDP-43, implicated in more than 90% of cases of MND, resulted in the death of motor neuron cells. This is the first time that scientists have been able to validate the direct effect of abnormal TDP-43 on human motor neurons.

The study, led by the University of Edinburgh’s (UK) Euan MacDonald Centre for Motor Neuron Disease Research, was performed in collaboration with King’s College London (UK), Columbia University (New York, NY, USA), and the University of San Francisco (CA, USA).

MND is a debilitating, untreatable, and ultimately lethal disorder that results from progressive loss of the motor nerves--motor neurons--that control speech movement, and breathing. Prof. Siddharthan Chandran, of the University of Edinburgh, said, “Using patient stem cells to model MND in a dish offers untold possibilities for how we study the cause of this terrible disease as well as accelerating drug discovery by providing a cost-effective way to test many thousands of potential treatments.”

The study, funded by the MND Association (Northampton, UK), was published ahead of print March 26, 2012, in the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS). Dr. Brian Dickie, director of research and development for the MND Association, said, “This advance is a significant milestone on the road to developing a laboratory model of MND that faithfully reflects the cellular events happening in the patient. “It is also a testament to the importance of international collaboration, with eminent scientists from leading institutions around the world focused on the common goal of understanding, and ultimately, defeating this devastating disease.”

Related Links:

University of Edinburgh
King’s College London
Columbia University







Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Electrolyte Analyzer
BKE-B
Manual Pipetting Aid
Pipette Controllers macro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers identified 157 metabolites linked to BBB damage, including 25 that appeared in at least two independent studies (Image Credit: Adobe Stock)

Blood Metabolite Patterns May Enable Early Detection of Blood-Brain Barrier Injury

Early injury to the blood-brain barrier (BBB) can precede many neurological disorders but remains difficult to detect noninvasively. Laboratory markers that identify barrier dysfunction before symptoms... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Blood Test for Lung Cancer Screening Receives FDA Breakthrough Device Designation

Lung cancer remains the leading cause of cancer death in the United States, yet only about 18% of people eligible for screening undergo low-dose computed tomography, the current guideline-recommended method.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.